Resistance of Bcr-Abl-positive leukemic stem cells (LSCs) to imatinib treatment in patients with chronic myeloid leukemia (CML) can cause relapse of disease and might be the origin for emerging drug-resistant clones. In this study, we identified Smo as a drug target in Bcr-Abl-positive LSCs. We show that Hedgehog signaling is activated in LSCs through upregulation of Smo. While Smo(-/-) does not impact long-term reconstitution of regular hematopoiesis, the development of retransplantable Bcr-Abl-positive leukemias was abolished in the absence of Smo expression. Pharmacological Smo inhibition reduced LSCs in vivo and enhanced time to relapse after end of treatment. Our results indicate that Smo inhibition might be an effective treatment strategy to reduce the LSC pool in CML.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ccr.2008.08.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of HOTAIR, HOXD8, HOXD9, HOXD11 gene expression levels in Turkish patients with acute and chronic myeloid leukemia: A single center experience.
Cell Mol Biol (Noisy-le-grand)
November 2024
Betül-Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Türkiye.
Homeobox (HOX) transcript antisense RNA (HOTAIR) and HOX genes are reported to be more expressed in various cancers in humans in recent studies. The role of HOTAIR and HOXD genes in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) is not well known. In this study, expression levels of HOXD8, HOXD9 and HOXD11 from HOXD gene family and HOTAIR were determined from peripheral blood samples of 30 AML and 30 CML patients and 20 healthy volunteers by quantitative Real Time PCR.
View Article and Find Full Text PDFThe CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy.
Front Immunol
December 2024
Université de Poitiers, Institut National de la Santé Et de la Recherche Médicale, Ischemie Reperfusion Métabolisme et Inflammation Stérile en Transplantation U1313, Poitiers, France.
Considering the general view that unconventional immune effectors play a major role in antitumor immunity, we recently postulated that the distinct new innate CD8 T-cell pool (co-expressing the transcription factor Eomesodermin and innate markers such as KIR/NKG2A) may counteract tumor cells, and thereby be potential target for cancer therapy. Here, to test this assumption, we used successfully targeted anti-leukemic therapy discontinuation (TFR) in chronic myeloid leukemia (CML). Numerical and functional status of innate CD8 T-cells, iNKT cells and γδ T-cells, in comparison with NK cells, was compared longitudinally between non-relapsed patients (i.
View Article and Find Full Text PDFImmune checkpoints PD1/PDL1, TIM3/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia.
Ann Hematol
December 2024
Laboratorio de Genética Hematológica, Instituto de Medicina Experimental, IMEX-CONICET/ Academia Nacional de Medicina, Pacheco de Melo 3081, Ciudad Autónoma de Buenos Aires, C1425AUM, Argentina.
Article Synopsis
- The immune system in chronic myeloid leukemia (CML) patients is significantly weakened, affecting their ability to respond to tumors, but shows improvement following effective treatment with tyrosine kinase inhibitors like imatinib.
- A study analyzed gene expression of various immune mediators in 171 blood samples from CML patients over their first year on imatinib, comparing it with samples from healthy donors.
- Results indicated that most immune mediators initially declined but largely normalized over time, while also revealing different patterns in optimal versus non-optimal treatment responders.
Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response.
Elife
November 2024
Division of Molecular Hematology, Lund Stem Cell Center, Lund University, Lund, Sweden.
The advent of tyrosine kinase inhibitors (TKIs) as treatment of chronic myeloid leukemia (CML) is a paradigm in molecularly targeted cancer therapy. Nonetheless, TKI-insensitive leukemia stem cells (LSCs) persist in most patients even after years of treatment and are imperative for disease progression as well as recurrence during treatment-free remission (TFR). Here, we have generated high-resolution single-cell multiomics maps from CML patients at diagnosis, retrospectively stratified by BCR::ABL1 (%) following 12 months of TKI therapy.
View Article and Find Full Text PDFPredicting drug resistance.
Elife
November 2024
Department of Internal Medicine and the Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, United States.
A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!